AstraZeneca PLC (NAS:AZN)
$ 67.62 0.42 (0.63%) Market Cap: 208.85 Bil Enterprise Value: 235.48 Bil PE Ratio: 32.60 PB Ratio: 5.34 GF Score: 92/100

AstraZeneca PLC BioPharmaceuticals Virtual Event - New CVRM: Emerging Pipeline Transcript

Mar 25, 2021 / 03:30PM GMT
Release Date Price: $49.7 (+1.87%)
Unidentified Company Representative

Think we can start. Hi, and welcome, everyone. Today's breakout session (inaudible), called New CVRM: Emerging Pipeline. I'm Thomas Larsen from AstraZeneca the Investor Relations team, and I will be the moderator to for this breakout session.

With me today, I have members from our bio-pharmaceutical team. We have Regina Fritsche Danielson, Senior VP for the early stage R&D. We have Tomas Andersson, VP late-stage R&D, and we have Lori Kreamer, VP, CRM biopharmaceuticals business unit.

This breakout session will last around 30 minutes, there will be a short presentation, followed by Q&A. As usual, the presentations are available on astrazeneca.com/investors, and we also sent the presentations to people on our distribution list.

Before I hand over to today's presenter, I would like to remind you that this meeting is being recorded, and that this event is for [south] side analysts and institutional investors only.

To ask a question in the webinar, please raise your hand using the icon on the menu bar. We will then open up your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot